Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Eur J Clin Invest. 2021 Nov;51(11):e13632. doi: 10.1111/eci.13632. Epub 2021 Aug 1.
There is preliminary evidence that individuals with previous SARS-CoV-2 infections exhibit a more pronounced antibody response. However, these assumptions have not yet been supported by data obtained through various CE-marked tests. This study aimed to close this gap.
Sixty-nine seronegatives and 12 individuals post-SARS-CoV-2 infection (tested by CE-labelled Roche NC immunoassay or PCR-confirmed assay) were included 21 ± 1 days after receiving the first dose of the Pfizer/BioNTech BNT162b2 vaccine. Antibody response to viral spike protein (S) was assessed by CE-labelled Roche S and DiaSorin S1/S2 assays and by a surrogate virus neutralization test (sVNT).
After a single dose of BNT162b2, individuals after natural SARS-CoV-2 infection presented with markedly higher anti-S levels than naïve individuals (Roche S: 9078.5 BAU/mL [5267.0-24 298.5] vs 79.6 [24.7-142.3]; and DiaSorin S1/S2: 1465.0 AU/mL [631.0-5365.0] vs 63.7 [47.8-87.5]) and showed all the maximum observed inhibition activity in the sVNT (98%), without overlaps between groups. There was a trend for higher responses in those with a more distant infection, although not statistically significant. The relative antibody increase after dose 2 was significantly higher among naïve individuals (25-fold), but antibody levels remained below that of seropositives.
Compared with naïve individuals, seropositives after natural SARS-CoV-2 infection presented with a substantially higher antibody response already after dose 1 of BNT162b2, as measured by two CE-marked in vitro diagnostic tests and a sVNT. These results should stimulate discussion and research on whether individuals after previous SARS-CoV-2 infection would benefit from a two-part vaccination schedule or whether these currently much-needed second doses could be saved.
有初步证据表明，先前感染过 SARS-CoV-2 的个体表现出更明显的抗体反应。然而，这些假设尚未得到通过各种获得 CE 标记的测试获得的数据的支持。本研究旨在填补这一空白。
69 名血清阴性者和 12 名 SARS-CoV-2 感染后个体（通过 CE 标记的罗氏 NC 免疫测定或 PCR 确认测定检测）在接受辉瑞/生物技术公司 BNT162b2 疫苗第一剂后 21±1 天纳入研究。通过 CE 标记的罗氏 S 和 DiaSorin S1/S2 测定以及替代病毒中和试验（sVNT）评估针对病毒刺突蛋白（S）的抗体反应。
在单次 BNT162b2 给药后，自然 SARS-CoV-2 感染后的个体的抗 S 水平明显高于未感染个体（罗氏 S：9078.5 BAU/mL [5267.0-24298.5] 比 79.6 [24.7-142.3]；和 DiaSorin S1/S2：1465.0 AU/mL [631.0-5365.0] 比 63.7 [47.8-87.5]），并且在 sVNT 中表现出所有观察到的最大抑制活性（98%），两组之间没有重叠。尽管没有统计学意义，但在感染时间较长的个体中，抗体反应呈上升趋势。与未感染个体相比，在接种第 2 剂后，未感染个体的抗体相对增加明显更高（25 倍），但抗体水平仍低于血清阳性者。
与未感染个体相比，自然 SARS-CoV-2 感染后的血清阳性者在接受 BNT162b2 第 1 剂后，通过两种 CE 标记的体外诊断测试和 sVNT 测量，已经表现出更高的抗体反应。这些结果应该会激发关于先前 SARS-CoV-2 感染个体是否受益于两部分疫苗接种方案或这些目前急需的第二剂疫苗是否可以节省的讨论和研究。
